Business
U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform
MOUNTAIN VIEW, Calif., May 06, 2025--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced that it has received an Issue Notification from the U.S. Patent and Trademark Office (USPTO) indicating that U.S. patent NO. 12,290,564, becomes effective today, May 6, 2025.
About this update from Renovorx, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/4b53f6a679139f3d732d518d5ab3cfc9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7WSq9gSXs.eDB01SOn_NgQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/4b53f6a679139f3d732d518d5ab3cfc9","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/GgvkALu4V53IaqucViKs2g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/4b53f6a679139f3d732d518d5ab3cfc9","width":1024,"height":512}},"lazy":false},{"type":"text","content":"Patent Expands Protection of TAMP therapy platform, Including Methods to Deliver an Agent, such as a Chemotherapeutic Drug, Near a Tumor","length":136,"tagName":"p","attribs":{}},{"type":"text","content":"RenovoRx Currently Holds a Strong and Growing IP Portfolio with 19 Issued Patents and 12 Pending Patents Supporting the Commercialization of RenovoCath Device","length":158,"tagName":"p","attribs":{}},{"type":"text","content":"MOUNTAIN VIEW, Calif., May 06, 2025--(BUSINESS WIRE)--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced that it has received an Issue Notification from the U.S. Patent and Trademark Office (USPTO) indicating that U.S. patent NO. 12,290,564, becomes effective today, May 6, 2025.","length":475,"tagName":"p"},{"type":"text","content":"This patent, titled "Methods for Treating Tumors," expands protection of methods for drug delivery with RenovoRx’s Trans-Arterial Micro-Perfusion (TAMP™) therapy platform, enabled by the Company’s proprietary RenovoCath device. The patent covers new methods for treating a tumor by delivering drugs locally to a region of an artery or blood vessel that is near the tumor after treating this region to reduce the microvasculature. The new patent provides protection through November of 2037.","length":500,"tagName":"p"},{"type":"text","content":"With its issuance, RenovoRx now holds a robust portfolio of 19 issued patents and 12 pending patents. Renov...